Labiotech: LongeVC's Sergey Jakimov and Artem Trotsyuk on What Investors Now Expect from AI Biotech Companies
LongeVC managing partner Sergey Jakimov and operating partner Artem Trotsyuk are featured in Labiotech's in-depth piece on how AI biotech investing has matured, and what separates fundable companies from science projects in 2026.
Artem describes the shift toward "asset-centric" companies: built around a defined biological problem, a specific disease indication, and a credible development pathway, rather than AI as the product itself. Sergey puts it directly: if you can't articulate a specific disease indication with measurable clinical endpoints, you don't have a drug.